Simulations Plus (NASDAQ:SLP) announced its quarterly earnings data on Sunday. The technology company reported $0.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01, MarketWatch Earnings reports. Simulations Plus had a return on equity of 24.44% and a net margin of 22.96%.
Shares of Simulations Plus stock traded down $8.28 on Tuesday, hitting $71.05. 23,687 shares of the company traded hands, compared to its average volume of 287,831. The company has a 50-day moving average price of $65.06 and a 200 day moving average price of $65.43. Simulations Plus has a 12-month low of $26.00 and a 12-month high of $83.78. The company has a market cap of $1.42 billion, a PE ratio of 152.38, a PEG ratio of 7.63 and a beta of -0.17.
In related news, CEO Shawn Oconnor sold 5,500 shares of the company’s stock in a transaction on Monday, November 23rd. The shares were sold at an average price of $56.25, for a total value of $309,375.00. Following the completion of the sale, the chief executive officer now directly owns 6,381 shares in the company, valued at $358,931.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Walter S. Woltosz sold 24,000 shares of the company’s stock in a transaction on Wednesday, December 23rd. The stock was sold at an average price of $72.71, for a total transaction of $1,745,040.00. Following the completion of the sale, the director now owns 4,659,614 shares of the company’s stock, valued at $338,800,533.94. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 64,881 shares of company stock worth $4,347,992. 31.57% of the stock is currently owned by corporate insiders.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.
Read More: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.